| Astellas and Theravance Announce Approval of VIBATIV TM ... - Market Wire (press release) |
|
|
Market Wire (press release)New onset or worsening renal impairment occurred in patients who received VIBATIV. Renal adverse events were more likely to occur in patients with baseline ...Astellas and Theravance Announce Approval of VIBATIV(TM) in Canada ... read more |